Skip to main content
. Author manuscript; available in PMC: 2020 Aug 4.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 Oct 4;20(2):130–135.e1. doi: 10.1016/j.clml.2019.08.013

Table 2. Population Pharmacokinetics of Melphalan.

Parameter Base RSE, % Age RSE, % P Creatinine CL RSE, % P
CL, L/h/m2   16.4 4.7   19.8 8.7 11.6 15.5
β a   –0.012 38.9 0.010         0.0036 42.9 .020
V, L/m2   14.5   6.5   14.4 7.3 14.6   6.5
Q, L/h/m2     4.8 23.3     5.2 25.9  4.8 29.1
V2, L/m2     8.9 12.9     8.9 14.7  8.7 15.4
σ Additive, mg/mL     0.0005 Fixed     0.0005 Fixed         0.0005 Fixed
σ Prop, CV%     0.32 6.9     0.31 6.6    0.31   6.4
—2 Log-Likelihood b 469.7 464.3 0.020 465.0 .030
IIV CV% RSE, % CV% RSE, % P CV% RSE, % P
CL 0.31 11.3 0.32 12.1 0.31 11.6
V 0.32 16.9 0.37 15.6 0.34 15.7
Q 0.85 21.8 0.97 22.0 0.93 27.4
V2 0.73 14.9 0.71 15.5 0.77 15.6

Abbreviations: CL = clearance; CV% = coefficient of variation; IIV = interindividual variability; Q = intercompartmental clearance; RSE = relative standard error; V = volume of distribution into the central compartment; V2 = volume of distribution into the peripheral compartment.

a

Covariate model: θ × exp (β × covariate).

b

P value represents the significance of the change in the —2 log likelihood (on the basis of the χ 2 test) relative to base model.